Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences, Inc. completed its merger effective November 17, 2026. CEO Frank D. Lee’s 660,830.841 reported common shares, including RSUs and 1,022.077 shares acquired under the Employee Stock Purchase Plan, converted into a right to receive the $36.50-per-share offer price, net of applicable withholding taxes and without interest.
Lee’s 692,512 options, with a $32.07 exercise price, were canceled and converted into a cash right based on any excess of the offer price over the exercise price, subject to withholding. Lee reported zero shares and options afterward; Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. director Alethia Young disposed of 17,798 common shares, including restricted stock unit awards, on November 17, 2026, when the merger became effective. The shares converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest, and her reported direct holdings fell to zero. Four option positions were canceled and converted into cash rights based on the excess, if any, of the offer price over the exercise price, subject to tax withholding; options with exercise prices at or above the offer price were canceled without consideration. Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. director Samit Hirawat reported dispositions at the November 17, 2026, effective time of the merger, which made Pacira a wholly owned subsidiary of Viatris. His 6,405 common shares, including RSU awards, converted into the right to receive $36.50 per share; his reported resulting balance was zero. Options covering 10,891 shares at a $23.42 exercise price and 39,291 shares at $19.85 were canceled and converted into cash rights based on the excess, if any, of the offer price over each exercise price, subject to tax withholding.
Pacira BioSciences, Inc. director Michael J. Yang reported dispositions on November 17, 2026, when the merger with Viatris became effective. Under the tender offer, 13,393 common shares were converted into the right to receive $36.50 per share. A further 6,405 shares issuable under restricted stock units were canceled for cash based on the offer price, subject to tax withholding. Four option awards covering 12,179, 11,279, 10,891 and 30,967 shares were canceled and converted into cash based on any excess of the offer price over each exercise price, subject to withholding. Options priced at or above the offer price were canceled without consideration; Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. Chief Administrative Officer Kristen Williams disposed of 167,062 common shares on November 17, 2026, in the merger. Each share converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest; her reported common-stock holding afterward was zero. Her reported options were canceled at the merger’s effective time; each listed exercise price exceeded the offer price, so the options were canceled with no consideration. No Rule 10b5-1 plan is reported.
Pacira BioSciences, Inc. chief commercial officer Brendan Teehan reported that 100,934 shares of common stock were disposed of on November 17, 2026, when each share converted into the right to receive the merger offer price of $36.50 per share, net of applicable withholding taxes and without interest. His reported common-stock balance afterward was zero. At the merger’s effective time, his options covering 99,500 shares, with a $26.59 per-share exercise price, were canceled and converted into a cash amount based on the excess, if any, of the offer price over the exercise price, subject to applicable tax withholding; the reported option balance afterward was zero. Pacira survived the merger as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. became a wholly owned subsidiary of Viatris Inc. on November 17, 2026, after Peach Purchaser Sub Inc. completed a cash tender offer and merged into Pacira. Director Christopher Christie disposed of 16,654 common shares, each converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest.
At the merger’s effective time, Christie's restricted stock units covering 6,405 shares were canceled and converted into cash based on the offer price, subject to tax withholding. His options were canceled; options with exercise prices below $36.50 per share converted into cash based on the positive difference between the offer price and exercise price, while options at or above that price were canceled for no consideration. No Rule 10b5-1 plan is reported.
Pacira BioSciences, Inc. CFO Shawn Cross reported three merger-related dispositions on November 17, 2026. His 9,210 common shares became a right to receive $36.50 per share, net of withholding and without interest; his RSU award covering 86,591 shares was canceled and converted to cash at the offer price, subject to tax withholding. His 150,000 options with a $16.45 exercise price were canceled for cash based on the excess, if any, of the offer price over the exercise price; his reported option position afterward was zero. Pacira became a wholly owned Viatris subsidiary.
Pacira BioSciences, Inc. (PCRX) director Mark Froimson reported the disposition of 20,136 common shares on November 17, 2026, in Viatris’ cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. At the merger’s effective time that day, 6,405 restricted stock units were canceled and converted into a cash right based on the shares issuable and the $36.50 offer price, subject to tax withholding. Nine option positions were canceled: options with exercise prices below the offer price converted into cash rights based on the difference between those prices; options at or above the offer price were canceled for no consideration. Pacira became a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. (PCRX) director Marcelo Bigal reported dispositions on November 17, 2026, in connection with the Viatris merger. He disposed of 11,393 common shares in the cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. His 6,405 shares issuable under restricted stock unit awards were canceled and converted into cash, subject to tax withholding.
Four option awards were canceled and converted into cash based on the excess, if any, of the $36.50 offer price over each exercise price: 12,179 options at $28.68; 11,279 at $24.34; 10,891 at $23.42; and 30,967 at $29.80 per share.